Bunkerhill ECG-EF vs Zio XT ECG Monitoring System
AI Verdict
Choose Bunkerhill ECG-EF if…
Choose Bunkerhill ECG-EF if you need a rapid, non-invasive screening tool to identify patients at risk for reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead ECGs. This tool is ideal for integrating into existing clinical workflows to aid in the early detection of heart failure risk without requiring specialized imaging.
View Bunkerhill ECG-EF →Choose Zio XT ECG Monitoring System if…
Choose Zio XT ECG Monitoring System if you require continuous, long-term cardiac monitoring (up to 14 days) to detect intermittent arrhythmias or evaluate symptomatic events that may not be captured during a brief office visit. Its wearable, wire-free design enhances patient comfort and compliance, making it suitable for diagnosing elusive cardiac conditions in an ambulatory setting.
View Zio XT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Bunkerhill ECG-EF | Zio XT ECG Monitoring System |
|---|---|---|
| Pricing | Contact sales for pricing details. | Contact for pricing |
| Deployment | Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs. | Cloud-based (AWS EC2 platform), no on-premise hardware required. |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio XT ECG Monitoring SystemTool B (Zio XT) offers superior patient usability with its wearable, wire-free, and water-resistant biosensor, leading to high patient compliance and comfort for continuous monitoring. While Tool A (Bunkerhill ECG-EF) focuses on seamless EHR integration for clinicians, Tool B's design directly addresses the patient experience for a diagnostic device.
Clinical Value
TieBoth tools offer significant clinical value by addressing different, yet crucial, cardiac diagnostic needs. Tool A (Bunkerhill ECG-EF) provides early identification of reduced LVEF from routine ECGs, aiding in heart failure risk assessment. Tool B (Zio XT) offers continuous monitoring for up to 14 days, which is critical for accurate arrhythmia detection and diagnosis, often catching intermittent events missed by single-point tests.
Pricing & Value
Zio XT ECG Monitoring SystemTool B (Zio XT) demonstrates greater transparency in its pricing, providing specific cost examples for the UK and proposed Medicare rates for the US, including relevant CPT codes. Tool A (Bunkerhill ECG-EF) only states 'contact for pricing,' offering no initial insight into its cost structure, making it harder to assess its value proposition upfront.
Enterprise Readiness
TieBoth tools exhibit strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering BAAs. Tool A (Bunkerhill ECG-EF) emphasizes seamless integration with existing EHRs and clinical archives, while Tool B (Zio XT) highlights its cloud-based deployment with no on-premise hardware. Both approaches simplify adoption for healthcare enterprises, catering to different IT preferences.
Innovation
Bunkerhill ECG-EFTool A (Bunkerhill ECG-EF) demonstrates a significant innovation by leveraging 'Generative AI' to extract a critical new insight (reduced LVEF) from widely available, routine 12-lead ECGs, effectively transforming an existing test into a powerful screening tool for heart failure. While Tool B (Zio XT) innovates with its wearable form factor and continuous monitoring, Tool A's ability to derive novel clinical value from existing data represents a broader and potentially more impactful paradigm shift in diagnostic utilization.
Support & Docs
Zio XT ECG Monitoring SystemBased on web searches, Tool B (Zio XT) from iRhythm Technologies appears to offer more readily accessible and structured support resources, including dedicated sections for patients and clinicians, FAQs, and contact information on its public website. Tool A (Bunkerhill Health) does not have as clearly defined or easily discoverable public support and documentation channels.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Bunkerhill ECG-EF | Zio XT ECG Monitoring System |
|---|---|---|
| Name | Bunkerhill ECG-EF | Zio XT ECG Monitoring System |
| Company | BunkerHill Health | iRhythm Technologies |
| Description | FDA-cleared artificial intelligence algorithm by BunkerHill Health that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure. | The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. |
| Key Functionality | AI algorithm to detect reduced Left Ventricular Ejection Fraction (LVEF u2264 40%) from 12-lead ECG data. | Wearable single-lead ECG biosensor for continuous ambulatory cardiac monitoring (up to 14 days) and arrhythmia detection. |
| Categories | Cardiology AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
Videos
Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and Zio XT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring Bunkerhill ECG-EF or Zio XT ECG Monitoring System
Backers
Who funded each tool's parent company.